research reports and media, page-349

from the prospectus... not sure what the confusion over the meaning of the term "exclusive"

bene pharmaChem Supply Agreement with Paradigm Paradigm has entered a 10 year supply agreement (with an option to extend for a further 10 years provided that within the first 10 years Paradigm has obtained regulatory approval for sale of a product incorporating PPS) with bene pharmaChem. (Supply Agreement) which includes the following key terms:

> within the territory: Pursuant to the Supply Agreement, Paradigm has agreed to exclusively purchase from bene pharmaChem and bene pharmaChem has agreed to supply exclusively to Paradigm, PPS (in bulk ware form) for use within the Territory (Australia, New Zealand, Philippines, Indonesia, Thailand, Singapore, Vietnam, Taiwan, Myanmar (Burma), Brunei (Darussalam), Cambodia, Laos and Malaysia) within the Field (Bone Marrow Edema, Asthma, Rhinitis and chronic obstructive pulmonary disease). In addition to the agreed purchase price, Paradigm agrees to pay bene pharmaChem a commercial rate of royalties on net sales of products by Paradigm (made by Paradigm using this PPS) throughout the term of the Agreement.

> outside the territory Where Paradigm pursues regulatory approval for commercial sale of products incorporating PPS outside the Territory and within the Field, bene pharmaChem has a first right of refusal for 90 days to supply Paradigm with bene pharma